AI-Driven Aggregation & Viscosity Prediction Service

Are you grappling with extended therapeutic antibody development cycles or unexpected late-stage failures due to aggregation and high viscosity? Creative Biolabs' AI-Driven Aggregation and Viscosity Prediction Service revolutionizes your process by accelerating candidate selection and ensuring stable, manufacturable biologics. We leverage advanced AI models for precise 3D structure prediction, molecular docking, and iterative optimization, all rigorously validated through wet lab experiments to meet your specific functional and developability needs.

How Creative Biolabs' Service Can Assist Your Project?

Creative Biolabs provides a comprehensive solution to de-risk your therapeutic antibody development. Our service enables early identification of stable and manufacturable antibody candidates, significantly reducing the likelihood of costly late-stage failures. We deliver optimized antibody sequences and structures, facilitating improved formulation development and ultimately enhancing the patient experience through more convenient drug administration.

Workflow

Learn how our expertise can advance your project — Request A Consultation Today!

Why Choose Us?

• Proprietary AlphaFold-Based AI Platform: Our advanced AI platform goes beyond standard prediction. Built upon and extending the capabilities of AlphaFold, it offers unparalleled accuracy in predicting complex 3D protein structures and their dynamic interactions. This allows for precise molecular docking and comprehensive analysis of physicochemical properties, enabling us to conduct more sophisticated structural design and property optimization.
• Iterative AI-Wet Lab Loop: We don't just predict; we validate and learn. Our integrated approach ensures that every AI prediction is rigorously verified through in-house wet lab experiments. These crucial experimental results are then fed back into our AI models, creating a continuous learning loop that perpetually refines and enhances the predictive power and optimization capabilities of our platform. This unique feedback mechanism guarantees the highest level of accuracy and real-world applicability.
• Accelerated Development & Reduced Risk: By leveraging our AI-driven insights, we can identify and optimize developable antibody candidates at an unprecedented pace. This drastically reduces the time and resources traditionally spent on experimental screening and minimizes the risk of costly late-stage failures due to unforeseen aggregation or viscosity issues.
• able for clinical development and manufacturability.
• Unrivaled Expertise: With over 20 years of specialized experience in biology and biopharmaceutical development, our team of scientists brings profound scientific knowledge and practical insights to every project. We understand the nuances of antibody design and developability, translating complex data into actionable strategies for our clients.

Advance your project with Creative Biolabs – Get Your Quote Now!

Introduction of AI-Driven Aggregation and Viscosity Prediction Service

The development of therapeutic antibodies is notoriously challenging, characterized by high costs, lengthy timelines, and low success rates, with up to 40% failing in late clinical trials due to unforeseen developability issues like aggregation and high viscosity. These challenges arise from the complex biophysical properties of antibodies, which influence their stability, manufacturability, and safety. Traditional low-throughput experimental screens are inadequate for navigating the vast antibody sequence space. However, the introduction of AI, especially ML and DL, is transforming antibody design by integrating high-throughput virtual screening with physics-based simulations and closed-loop experimental validation, facilitating rapid and accurate candidate identification. Creative Biolabs' AI-Driven Aggregation and Viscosity Prediction Service tackles these challenges by utilizing ML models to predict and optimize antibody developability, integrating computational insights with rigorous experimental verification to accelerate the creation of stable, manufacturable biologics, thereby expediting the delivery of transformative therapies.

Fig.1 Protein conformational dynamics leading to folding and aggregation.¹

Frequently Asked Questions

Q1: How does Creative Biolabs' AI service specifically address antibody aggregation?

A: Our AI models analyze detailed antibody sequence features and predicted 3D structures to identify potential aggregation-prone regions. By understanding the underlying molecular forces, our AI proposes precise modifications to reduce aggregation propensity. These AI-predicted improvements are then rigorously confirmed through experimental validation in our wet lab, ensuring reliable and effective solutions.

Q2: Can your service predict viscosity for high-concentration antibody formulations?

A: Absolutely. Our advanced AI models are specifically trained on extensive datasets, incorporating structural features derived from molecular dynamics simulations, to accurately predict and classify antibody viscosity. This is crucial for developing high-concentration formulations suitable for convenient subcutaneous delivery, and our predictions are continuously refined with real experimental data.

Q3: What makes Creative Biolabs' AI platform unique compared to other solutions in the market?

A: Creative Biolabs' AI platform is built upon and significantly extends the capabilities of models like AlphaFold. Our unique architecture not only predicts highly accurate 3D protein structures but also performs sophisticated molecular docking. More importantly, we operate with an iterative AI-wet lab feedback loop, where every AI prediction is verified experimentally, and these results in turn optimize our AI models for continuous improvement and unparalleled accuracy in antibody property optimization.

Q4: Is the AI prediction process validated experimentally, or is it purely computational?

A: It is a hybrid and integrated approach. All AI predictions made by our platform are rigorously verified through our in-house wet lab experiments. These verification results are critical; they are meticulously fed back into our AI models. This continuous learning cycle allows us to constantly refine and enhance the predictive accuracy and optimization capabilities of our AI, ensuring real-world applicability.

Q5: What kind of antibodies can benefit most from this AI-driven developability service?

A: Our service is highly beneficial for a wide range of therapeutic antibody projects. This includes novel antibody candidates in early discovery that require de-risking for developability, as well as existing antibodies that need optimization for enhanced stability, reduced viscosity, improved manufacturability, or to meet specific functional and clinical development needs.

Creative Biolabs' AI-Driven Aggregation and Viscosity Prediction Service stands as a testament to our commitment to accelerating and de-risking therapeutic antibody development. By seamlessly integrating advanced AI models for precise 3D structure prediction and property optimization with robust wet lab validation, we provide unparalleled insights and solutions for enhancing antibody stability, manufacturability, and patient experience. Ready to transform your antibody development pipeline? Reach out to Creative Biolabs today to learn how our cutting-edge AI capabilities can empower your projects.

Reference

1. Li W, Prabakaran P, Chen W, Zhu Z, Feng Y, Dimitrov DS. Antibody Aggregation: Insights from Sequence and Structure. Antibodies (Basel). 2016 Sep 5;5(3):19. DOI: 10.3390/antib5030019. Distributed under Open Access license CC BY 4.0, without modification.